{"prompt": "['Documentation that subject meets eligibility criteria, i.e. history, physical examination, and', 'confirmation of diagnosis (to support inclusion and exclusion criteria);', 'Documentation of the reason(s) a consented subject is not enrolled', 'Participation in study (including study number);', 'Study discussed and date of informed consent;', 'Dates of all visits;', 'Documentation that protocol specific procedures were performed;', 'Results of efficacy parameters, as required by the protocol;', 'Start and end date (including dose regimen) of study drug, including dates of dispensing and', 'return;', 'Record of all adverse events and other safety parameters (start and end date, and including', 'causality and severity);', 'Concomitant medication (including start and end date, dose if relevant, dose changes);', 'Date of study completion and reason for early discontinuation, if it occurs.', 'All clinical study documents will be retained by the Sponsor-Investigator until 2 years after the', 'investigation is discontinued and regulatory authorities have been notified.', '11.6 Case Report Forms', 'For each subject consented, an eCRF will be completed by an authorized study staff member whose', 'training for this function is documented according to study procedures. eCRF will be completed within', 'three days of the subject visit to enable the Sponsor-Investigator to perform central monitoring of safety', 'data. Subsequent to data entry, a study monitor will perform source data verification for select data', 'points in accordance with the monitoring plan within the EDC system. Original entries as well as any', 'changes to data fields will be stored in the audit trail of the system. Prior to database lock (or any interim', 'time points as described in the clinical data management plan), the Sponsor-Investigator will use his/her', 'log in credentials to confirm that the forms have been reviewed, and that the entries accurately reflect', 'the information in the source documents. The eCRF capture the data required per the protocol schedule', 'of events and procedures. System-generated or manual queries will be issued to the investigative site', 'staff as data discrepancies are identified by the monitor or internal CRI staff, who routinely review the', 'data for completeness, correctness, and consistency. A read-only archive copy of the case report form', 'will be stored in accordance with the records retention requirements outlined in Section 11.5.', 'Study data will be collected and managed using REDCap electronic data capture tools hosted by Boston', 'Computing Network (Harris et al. 2009). REDCap (Research Electronic Data Capture) is a secure, web-', 'based application designed to support data capture for research studies, providing: 1) an intuitive', 'interface for validated data entry; 2) audit trails for tracking data manipulation and export procedures; 3)', 'automated export procedures for seamless data downloads to common statistical packages; and 4)', 'procedures for importing data from external sources. It satisfies HIPAA-Security guidelines and is 21 CFR', 'Part 11 capable, with compliance assured by the Community Research Initiative Information Technology', 'Department and Boston Computing Network. Data will be exported from REDCap to the statistician for', 'statistical analysis will be de-identified.', '11.7 Investigational Medicinal Product Accountability and Return', 'All used and unused study drug supplies will be destroyed by the study monitor or designee in', 'accordance to the Sponsor-Investigator standard operating procedures. The Sponsor-Investigator must', 'maintain accurate records for all study drug destroyed. Records must show the identification and', 'CRI 15-05 Protocol 13SEP2017', 'Page 41']['quantity of each unit destroyed, the method of destruction, and the person who disposed of the study', 'drug. Upon study completion, copies of the study drug accountability records must be filed at the site.', '11.8 Protocol Compliance', 'The Sponsor-Investigator is responsible for ensuring the study is conducted in accordance with the', 'procedures and evaluations described in this protocol.', '11.9 Protocol Modifications', 'All protocol modifications will be submitted to the IRB/IEC in accordance with local requirements and', 'receive documented IRB/IEC approval before modifications can be implemented.', '11.10 Study Monitoring', 'In accordance with regulations and guidelines, the Sponsor-Investigator is responsible for assuring', 'ongoing monitoring of the study. The designated study monitor will have direct access to the Sponsor-', \"Investigator's source documentation in order to verify the accuracy of the data recorded in the eCRF.\", 'The monitor is responsible for routine review of the eCRF at regular intervals throughout the study to', 'verify adherence to the protocol and the completeness, consistency, and accuracy of the data being', 'entered on them. The monitor will have access to any subject records needed to verify the entries on the', 'eCRF.', '11.11 Study Auditing or Inspections', 'Representatives of regulatory authorities may conduct inspections or audits of the clinical study. If the', 'Sponsor-Investigator is notified of an inspection by a regulatory authority the Sponsor-Investigator will', 'notify the CRI Medical Monitor and Regulatory Sponsor staff immediately. The Sponsor-Investigator will', 'make available all source documents and other records for this trial to appointed study monitors, to', 'IRBs/IECs or to regulatory authority or health authority inspectors.', '11.12 Study Discontinuation', 'The Sponsor-Investigator reserves the right to terminate the study at any time. Should this be necessary,', 'discontinuation procedures will be arranged and the appropriate regulatory authority(ies), IRBs, and IECs', 'will be notified. In terminating the study, the Sponsor-Investigator will assure that adequate', \"consideration is given to the protection of the subjects' interests.\", '11.13 Finance and Insurance', 'No funds have been set aside for payment of treatment of any injury or illness that occurs as a direct', \"result in a subject's participation in this study. No funds have been appropriated for other associated\", \"losses such as lost wages, disability or discomfort related to an injury or illness as a result of a subject's\", 'participation in this study. In the event that a subject experiences an injury or illness as described above,', 'they should be immediately referred to their primary care provider for treatment. The subject will be', 'responsible for payment of cost of treatment.', '11.14 Study Report and Publications', 'A clinical study report will be prepared and provided to the regulatory agency(ies). The Sponsor-', 'Investigator will ensure that the report meets the standards set out in the ICH Guideline for Structure', 'and Content of Clinical Study Reports (ICH E3). Note that an abbreviated report may be prepared in', 'certain cases.', 'CRI 15-05 Protocol 13SEP2017', 'Page 42']\n\n###\n\n", "completion": "END"}